(Sharecast News) - Drugmaker GSK said on Monday that it has struck an exclusive agreement with Sino Biopharmaceutical subsidiary Chia Tai Tianqing Pharmaceutical to accelerate its chronic hepatitis B treatment, bepirovirsen, in mainland China.
GSK said that under the agreement, CTTQ will be responsible for importation, distribution, hospital access, and promotional...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE